Evidence map›Paper›PMID 40767951›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

Marc-David Künnemann, Christian Römer, Anne Helfen, Annalen Bleckmann, Marcel Kemper, Walter Heindel, Tobias J Brix, Michael Forsting, Johannes Haubold, Marcel Opitz and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marc-David KünnemannClinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany.
Christian RömerClinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany.ORCID 0000-0003-4386-9323
Anne HelfenClinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany.
Annalen BleckmannWest German Cancer Center (WTZ), University Hospital Münster, Münster, Germany.
Marcel KemperWest German Cancer Center (WTZ), University Hospital Münster, Münster, Germany.
Walter HeindelClinic for Radiology, University of Münster and University Hospital Münster, Münster, Germany.
Tobias J BrixInstitute of Medical Informatics, University of Münster, Münster, Germany.
Michael ForstingInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Johannes HauboldInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Marcel OpitzInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Martin SchulerWest German Cancer Center (WTZ), Department of Medical Oncology, University Hospital Essen, Essen, Germany.
Felix NensaInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Katarzyna BorysInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.ORCID 0000-0001-6987-6041
René HoschInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.ORCID 0000-0003-1760-2342

Funding

German Netzwerk Universitätsmedizin 01KX2121
6 · The paper itself

Abstract

backgroundAI-driven automated body composition analysis (BCA) may provide quantitative prognostic biomarkers derived from routine staging CTs. This two-centre study evaluates the prognostic value of these volumetric markers for overall survival in lung cancer patients.

methodsLung cancer cohorts from Hospital A (n = 3345, median age 65, 86% NSCLC, 40% M1, 40% female) and B (n = 1364, median age 66, 87% NSCLC, 37% M1, 38% female) underwent automated BCA of abdominal CTs ±60 days of primary diagnosis. A deep learning network segmented muscle, bone and adipose tissues (visceral = VAT, subcutaneous = SAT, intra-/intermuscular = IMAT and total = TAT) to derive three markers: Sarcopenia Index (SI = Muscle/Bone), Myosteatotic Fat Index (MFI = IMAT/TAT) and Abdominal Fat Index (AFI = VAT/SAT). Kaplan-Meier survival analysis, Cox proportional hazards modelling and machine learning-based survival prediction were performed. A survival model including clinical data (BMI, ECOG, L3-SMI, -SATI, -VATI and -IMATI) was fitted on Hospital A data and validated on Hospital B data.

resultsIn nonmetastatic NSCLC, high SI predicted longer survival across centres for males (Hospital A: 24.6 vs. 46.0 months; Hospital B: 13.3 vs. 28.9 months; both p < 0.001) and females (Hospital A: 37.9 vs. 53.6 months, p = 0.008; Hospital B: 23.0 vs. 28.6 months, p = 0.018). High MFI indicated reduced survival in males at both hospitals (Hospital A: 43.7 vs. 28.2 months; Hospital B: 28.8 vs. 14.3 months; both p ≤ 0.001) but showed center-dependent effects in females (significant only in Hospital A, p < 0.01). In metastatic disease, SI remained prognostic for males at both centres (p < 0.05), while MFI was significant only in Hospital A (p ≤ 0.001) and AFI only in Hospital B (p = 0.042). Multivariate Cox regression confirmed that higher SI was protective (A: HR 0.53, B: 0.59, p ≤ 0.001), while MFI was associated with shorter survival (A: HR 1.31, B: 1.12, p < 0.01). The multivariate survival model trained on Hospital A's data demonstrated prognostic differentiation of groups in internal (n = 209, p ≤ 0.001) and external (Hospital B, n = 361, p = 0.044) validation, with SI feature importance (0.037) ranking below ECOG (0.082) and M-status (0.078), outperforming all other features including conventional L3-single-slice measurements.

conclusionCT-based volumetric BCA provides prognostic biomarkers in lung cancer with varying significance by sex, disease stage and centre. SI was the strongest prognostic marker, outperforming conventional L3-based measurements, while fat-related markers showed varying associations. Our multivariate model suggests that BCA markers, particularly SI, may enhance risk stratification in lung cancer, pending centre-specific and sex-specific validation. Integration of these markers into clinical workflows could enable personalized care and targeted interventions for high-risk patients.

Indexed as

Body CompositionLung NeoplasmsTomography, X-Ray ComputedAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisbody composition analysisdeep learninglung cancermyosteatosissarcopenia

Identifiers

PMID40767951
PMCPMC12327357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.